S&P/ASX 200 Index (ASX: XJO) shares are down 0.25% to 8,861.4 points on Wednesday.
Meanwhile, three analysts share their views and ratings on three ASX shares.
Let's take a look.

Image source: Getty Images
Paladin Energy Ltd (ASX: PDN)
The Paladin Energy share price is $7.04, up 4.3% today and down 10% over 12 months.
Morgans maintained a buy rating on this ASX uranium share following Paladin's $525 million capital raise at $7.80 per share.
Morgans analyst, Christopher Creech, said:
This raise will materially strengthen the balance sheet and remove a key component of funding uncertainty surrounding PLS [Patterson Lake South].
Funds will be directed towards PLS development activities, including detailed engineering, procurement of long-lead items (Tunnel Boring Machine, Gas Turbines etc), underground development and site readiness works, while also supporting resource growth drilling at Triple R and exploration across the Athabasca Basin.
Creech reduced his 12-month price target on Paladin Energy shares from $13.10 to $11.25.
This still implies outstanding potential upside of almost 60%.
Official Australian Government forecasts show the uranium price is set to rise 38% by FY31.
Accent Group Ltd (ASX: AX1)
The Accent share price is steady at 65 cents on Wednesday, and down 45% over 12 months.
Morgans downgraded Accent shares from accumulate to hold after reviewing the shoe retailer's trading update.
Management said shoe sales had moderated in recent months due to lower consumer confidence.
Morgans analyst, Emily Porter, reckons $30 million in cost savings already implemented for FY27 won't generate as big a benefit in these trading conditions.
Thus, Porter cut her rating on this ASX consumer discretionary share and reduced her 12-month target from 77 cents to 68 cents.
This implies the stock is close to fully valued now.
Porter said:
Whilst we do think the share price undervalues the longer-term potential of the business, we see limited reason for the stock to re-rate in the near term.
Sigma Healthcare Ltd (ASX: SIG)
The Sigma Healthcare share price is $2.91, up 0.2% today and down 0.5% over 12 months.
Sigma Healthcare is a pharmacy franchisor and product wholesaler that owns Chemist Warehouse, Amcal, and Discount Drug Stores.
The company merged with Chemist Warehouse in early 2025.
In its first full financial year since the merger, Sigma delivered a 22% increase in normalised net profit after tax to $732.3 million.
In a trading update, Sigma reported a 12% increase in sales at Australian Chemist Warehouse stores between 1 July and 16 October.
However, Tony Locantro from Alto Capital is concerned about the ASX healthcare share's valuation.
The Sigma Healthcare share price has jumped 14% in two months.
He explains his sell rating (courtesy The Bull) this week:
In our view, the company was recently trading on a lofty valuation, leaving little room for slower pharmacy sales or delays in realising merger savings.
At recent prices, it's worth considering taking some profits.